Specific SSRIs and birth defects: bayesian analysis to interpret new data in the context of previous reports
暂无分享,去创建一个
Jan M Friedman | Owen Devine | Jennita Reefhuis | O. Devine | J. Reefhuis | J. Friedman | M. Honein | Margaret A Honein | Carol Louik | C. Louik
[1] L D Edmonds,et al. The National Birth Defects Prevention Study , 2001, Public health reports.
[2] K R Abrams,et al. Bayesian methods in meta-analysis and evidence synthesis. , 2001, Statistical methods in medical research.
[3] R. Kirby,et al. Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006. , 2010, Birth defects research. Part A, Clinical and molecular teratology.
[4] J. Goodman,et al. Women's attitudes, preferences, and perceived barriers to treatment for perinatal depression. , 2009, Birth.
[5] David J. Lunn,et al. The BUGS Book: A Practical Introduction to Bayesian Analysis , 2013 .
[6] A. Scialli,et al. Teratogenic exposures , 2011, American journal of medical genetics. Part C, Seminars in medical genetics.
[7] A. Olshan,et al. The National Birth Defects Prevention Study: A review of the methods. , 2015, Birth defects research. Part A, Clinical and molecular teratology.
[8] S. Hernández-Díaz,et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. , 2007, The New England journal of medicine.
[9] Lilah M. Besser,et al. Diabetes mellitus and birth defects. , 2008, American journal of obstetrics and gynecology.
[10] B. Källén,et al. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data , 2010, Psychological Medicine.
[11] A. Abuhamad,et al. ACOG Practice Bulletin, clinical management guidelines for obstetrician-gynecologists number 98, October 2008 (replaces Practice Bulletin number 58, December 2004). Ultrasonography in pregnancy. , 2008, Obstetrics and gynecology.
[12] I. Wilson,et al. Antidepressant Use: Concordance Between Self-Report and Claims Records , 2003, Medical care.
[13] Meghan T. Frey,et al. Prevalence of Prescription Medication Use Among Non-pregnant Women of Childbearing Age and Pregnant Women in the United States: NHANES, 1999–2006 , 2015, Maternal and Child Health Journal.
[14] R. Lowry,et al. Folic acid fortification and the birth prevalence of congenital heart defect cases in Alberta, Canada. , 2013, Birth defects research. Part A, Clinical and molecular teratology.
[15] M. Nørgaard,et al. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis , 2010, Clinical epidemiology.
[16] Jan M Friedman,et al. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. , 2007, The New England journal of medicine.
[17] M. Gissler,et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design , 2015, BMJ : British Medical Journal.
[18] T. Woodruff,et al. Evaluating the health significance of hazardous air pollutants using monitoring data. , 2001, Public health reports.
[19] I. Anderson,et al. Systematic Review and Guide to Selection of Selective Serotonin Reuptake Inhibitors , 1999, Drugs.
[20] S. Rasmussen,et al. Guidelines for case classification for the National Birth Defects Prevention Study. , 2003, Birth defects research. Part A, Clinical and molecular teratology.
[21] S. Rasmussen,et al. Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn. , 2006, The New England journal of medicine.
[22] I. Petersen,et al. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. , 2012, Obstetrics and gynecology.
[23] Mary K. Kowal,et al. National trends in antidepressant medication treatment among publicly insured pregnant women. , 2013, General hospital psychiatry.
[24] P. Hallberg,et al. Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn. , 2006, The New England journal of medicine.
[25] A. Olshan,et al. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. , 2010, Birth defects research. Part A, Clinical and molecular teratology.
[26] T. Sadler. Selective serotonin reuptake inhibitors (SSRIs) and heart defects: potential mechanisms for the observed associations. , 2011, Reproductive toxicology.
[27] Cosma Rohilla Shalizi,et al. Philosophy and the practice of Bayesian statistics. , 2010, The British journal of mathematical and statistical psychology.
[28] S. Gentile. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of birth defects , 2011, Acta psychiatrica Scandinavica.
[29] Wilhelmina S Kerstjens-Frederikse,et al. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. , 2009, Birth defects research. Part A, Clinical and molecular teratology.
[30] S. Shapiro,et al. Effect of questionnaire design on recall of drug exposure in pregnancy. , 1986, American journal of epidemiology.
[31] B. Ottesen,et al. Ultrasonography in pregnancy , 1994, Ugeskrift for laeger.
[32] K J Rothman,et al. No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.
[33] S. Rasmussen,et al. Patterns of Antidepressant Medication Use Among Pregnant Women in a United States Population , 2011, Journal of clinical pharmacology.